https://doi.org/10.4081/hls.2024.12723
The effectiveness of risperidone on PANSS score and IL-6 in confirmed COVID-19 schizophrenic patients
Submitted: 15 June 2024
Accepted: 10 July 2024
Published: 22 July 2024
Accepted: 10 July 2024
Abstract Views: 0
PDF: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The study aimed to determine the efficacy of risperidone on PANSS scores and Interleukin 6 (IL-6) levels in schizophrenia patients with confirmed COVID-19. The study type was analytical observational, with a prospective cohort design. The subjects included inpatient Schizophrenia patients with and without COVID-19, mild-moderate and asymptomatic COVID-19, and schizophrenic patients without COVID-19 who were hospitalized and met the inclusion and exclusion criteria, for a total of 22 subjects in each group. The Positive and Negative Syndrome Scale (PANSS) and Elisa Interleukin 6 (IL-6) serum were sampled consecutively for this study. In the positive covid-19 group, the Mean IL-6 Post was significantly lower than Pre (23.0 vs. 26.1, p<0.001), while in the control group, the Mean IL-6 Post (four weeks) was significantly lower than Pre (baseline), with 19.3 vs. 21.0 (p<0.001). Serum IL-6 levels appeared to be an effective prognostic biomarker in COVID-19 patients. The 35 pg/mL cut-off point could distinguish mild-moderate patients from more severe ones. We discovered that schizophrenia patients with verified positive COVID-19 received COVID-19 therapy in the form of a combination of antipsychotic and antivirals had IL-6 levels lower than 35 pg/mL, indicating the role of antipsychotic (risperidone) and antiviral in reducing IL-6 levels.
Badan Pusat Statistik Provinsi Sulawesi Selatan. Perilaku Masyarakat pada Masa Pandemi COVID-19 Provinsi Sulawesi Selatan. 2022; 1–53
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020;215:108448.
Diao B, Wang C, Wang R, et al. Human kidney is a target for novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection Running title: SARS-CoV-2 infects human kidney. MedrxivOrg 2020;12:2506.
Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy Eur J Allergy Clin Immunol 2020;75:2445–76.
Guo Q, Zheng Y, Shi J, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: A mixed-method study. Brain Behav Immun 2020;88:17–27.
Guirao JJ, Cabrera CM, Jiménez N, et al. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Mol Immunol 2020;128:64-8.
World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. World Health Organization. 2020. Avaiable from: https://iris.who.int/handle/10665/331506
May M, Slitzky M, Rostama B, et al. Antipsychotic-induced immune dysfunction: A consideration for COVID-19 risk. Brain, Behav Immun - Heal 2020;6:100097.
Patel KR, Cherian J, Gohil K, et al. Schizophrenia: Overview and treatment options. P T 2014;39:638–645
Fitrikasari A, Kartikasari L. Buku Ajar Skizofrenia. UNDIP Press Semarang; 2022. Available from: https://doc-pak.undip.ac.id/id/eprint/18409/1/Buku%20Ajar%20Skizofrenia%20FINAL.pdf
Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuro-Psychopharmacology Biol Psychiatry 2013;42:115–121.
Müller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci 2015;9:372.
Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry 2013;42:20–34.
Radtke FA, Chapman G, Hall J, et al. Modulating neuroinflammation to treat neuropsychiatric disorders. Biomed Res Int 2017;2017:5071786.
Quincozes-Santos A, Abib RT, Leite MC, et al. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol Cell Biochem 2008;314:59–63.
Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther 2020;5:1–8.
Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry 2020;7:1025–31.
Videbeck SL. The eighth edition of Psychiatric–Mental Health Nursing. LWW; 2020.
de Souza DF, Wartchow K, Hansen F, et al. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuro-Psychopharmacology Biol Psychiatry 2013;43:14–22.
Noto MN, Maes M, Nunes SOV, et al. Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. Eur Neuropsychopharmacol 2019;29:416–31.
Al-Amin MM, Choudhury MFR, Chowdhury AS, et al. Pretreatment with risperidone ameliorates systemic LPS-induced oxidative stress in the cortex and hippocampus. Front Neurosci 2018;12:1–9.
Song X, Fan X, Li X, et al. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. Psychopharmacology (Berl) 2014;231:319–25.
Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228–33.
Zajkowska Z, Mondelli V. First-episode psychosis: An inflammatory state? Neuroimmunomodulation 2014;21:102–8.
Zhou X, Tian B, Han H Bin. Serum interleukin-6 in schizophrenia: A system review and meta-analysis. Cytokine 2021;141:155441.
Park JH, Park HJ, Lee SE, et al. Repositioning of the antipsychotic drug TFP for sepsis treatment. J Mol Med 2019;97:647-58.
Crespo-Facorro B, Ruiz-Veguilla M, Vázquez-Bourgon J, et al. Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis. Front Pharmacol 2021;12:1–8.
Lu Q, Zhu Z, Tan C, et al. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract 2021;75:1–8.
Li J, Rong L, Cui R, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. Ann Palliat Med 2021;10:3706–14.
Zhang J, Hao Y, Ou W, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med 2020;18:1–8.
Miller BJ, Gassama B, Sebastian D, et al. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects brian. Bone 2008;23:1–7.
How to Cite
Lisal, S. T., Hawaidah, H., Natalia, D., Seweng, A., Widaningsih, Y., Limoa, E., & Syamsuddin, S. (2024). The effectiveness of risperidone on PANSS score and IL-6 in confirmed COVID-19 schizophrenic patients. Healthcare in Low-Resource Settings. https://doi.org/10.4081/hls.2024.12723
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.